Product design software company PTC (NASDAQ:PTC) will be reporting earnings this Wednesday after market hours. Here’s what investors should know. PTC beat analysts’ revenue expectations by 10.4% last ...

BofA analyst Andrew Obin downgraded PTC (PTC) to Neutral from Buy with a price target of $208, down from $235. Initial FY26 constant currency annual recurring revenue growth guidance of 7%-9% ...

The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events ...

In trading on Thursday, shares of PTC Inc (Symbol: PTC) crossed below their 200 day moving average of $181.86, changing hands as low as $170.97 per share. PTC Inc shares are currently trading off ...

PTC Industries Limited is an India-based company, which is engaged in manufacturing of precision metal components for critical applications. It is primarily engaged in the manufacturing of metal ...

PTC, Inc. is a global software company, which engages in the provision of a portfolio of innovative digital solutions that work together to transform how physical products are engineered, manufactured ...

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved PTC's ...

The flip-flop, in whichever of its several forms you encounter it, is a staple of logic design. Any time that you need to hold onto something, count, or shift bits, out it comes. We expect a flip-flop ...

Mangaluru: A farmer from Alekkady in Murulya, Sullia, has launched a remarkable initiative to conserve the indigenous Malnad Gidda — a dwarf cattle breed — through a unique community-based adoption ...

PTC, Inc. is a global software company, which engages in the provision of a portfolio of innovative digital solutions that work together to transform how physical products are engineered, manufactured ...

Shares of product design software company PTC (NASDAQ:PTC) fell 7.5% in the morning session after the company's weak revenue forecast for the upcoming quarter overshadowed its strong third-quarter ...

In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...